Liver Transplant European Study Into the Prevention of Fungal Infection

Inclusion Criteria: * Undergoing orthotopic whole or split liver allograft transplantation * Patients at 'high risk' of invasive fungal infection due to the presence of at least one of the following risk factors: * Re-transplantation * Acute liver failure * Pre- or post-operative renal impairment (defined as creatinine clearance ≤40 ml/min) or need for renal replacement therapy * Admission to Intensive Care Unit (ICU) for greater than 48 hours prior to liver transplant * Re-operation (abdominal surgery) within 5 days of liver transplant * Presence of choledocojejunostomy * Perioperative colonization with fungi, defined as two or more positive clinical site surveillance cultures for Candida spp., obtained within 96 hours before or after liver transplant * Need for prolonged mechanical ventilation for greater than 48 hours following liver transplant * Transfusion intraoperatively of 20 or more units of cellular blood products * Female subject of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and must agree to maintain effective birth control during the study Exclusion Criteria: * Any systemic antifungal therapy (excluding fluconazole or oral nystatin for a maximum of 7 days) within 14 days prior to randomization * Evidence of documented ('proven' or 'probable') or suspected ('possible') IFD (according to the EORTC/MSG criteria) * Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal, or any of the study drugs or their excipients